--- title: "Supply of Endonucleases" ocid: "ocds-h6vhtk-06ace0" canonical_url: "https://d3tenders.com/contract/?ocid=ocds-h6vhtk-06ace0" markdown_url: "https://d3tenders.com/contract/ocds-h6vhtk-06ace0.md" json_url: "https://d3tenders.com/contract/ocds-h6vhtk-06ace0.json" source: "Find A Tender Service" current_stage: "Planning" buyer: "NHS BLOOD AND TRANSPLANT" published: "2026-06-03" --- # Supply of Endonucleases Buyer: NHS BLOOD AND TRANSPLANT Current stage: Planning OCID: ocds-h6vhtk-06ace0 [View canonical contract page](https://d3tenders.com/contract/?ocid=ocds-h6vhtk-06ace0) [Download OCDS JSON](https://d3tenders.com/contract/ocds-h6vhtk-06ace0.json) ## Summary The NHS Blood and Transplant, located in Bristol, is in the planning stage of a procurement process for the supply of endonucleases. This initiative is crucial for the Clinical Biotechnology Centre, which specialises in manufacturing investigational medicinal products such as advanced therapy medicinal products (ATMPs) and other biotechnological products. Prospective suppliers are invited to express their interest by 31st July 2026, with a future market engagement session scheduled for August 2026. The procurement relates to chemical reagents and media, and the projected contract value is approximately £87,500. The official procurement process is anticipated to commence with a formal notice by 1st October 2026. This tender offers significant opportunities for businesses involved in biotechnological manufacturing, particularly those with expertise in producing highly efficient and GMP-qualified endonucleases. SMEs with capabilities in developing analytical assays for endonuclease quantification and viral vector manufacturing will find this tender particularly relevant. The opportunity focuses on providing enzymes suitable for use in HEK293 suspension cell bioprocesses, requiring comprehensive technical documentation to support quality and performance standards. The contract period spans from January 2027 to December 2030, allowing for long-term collaboration and growth potential within this specialised market. ## Notice The Clinical Biotechnology Centre at NHS Blood and Transplant is an MHRA-licensed facility for the manufacture of investigational medicinal products, including advanced therapy medicinal products (ATMPs) and other biotechnology products such as plasmid DNA, viral vectors, and therapeutic proteins. The organisation intends to initiate a procurement process for the supply of advanced, high-performance, and cost-effective endonucleases to support the removal of nucleic acids from ATMPs, particularly gene therapy vectors, including adeno-associated viral (AAV) vectors and lentiviral vectors. The endonuclease must exhibit non-specific nuclease activity against a broad range of nucleic acid substrates, including DNA, RNA, plasmid DNA, synthetically produced DNA, enzymatically produced DNA, and other nucleic acid modalities used in viral vector manufacturing. The enzyme should retain activity under physiological pH and salt conditions, while also maintaining high enzymatic performance across a broad pH and salt concentration range. Demonstrated suitability for use in viral vector manufacturing processes employing HEK293 suspension cells cultured in stirred-tank bioreactors will be considered an advantage. Suppliers should also demonstrate that residual endonuclease can be efficiently removed from the viral vector product using a defined set of purification methods commonly applied in bioprocessing. A key requirement is the availability of GMP-qualified and validated analytical assays for the quantification of residual endonuclease at different stages of the manufacturing and purification process. The supplier must provide such assays either directly or through authorised analytical service providers. The supplier should be able to provide endonuclease in multiple quality grades, including R&D grade, GMP-compatible grade, and GMP-qualified grade. It is also essential that these materials are available in quantities suitable for small, medium and large-scale production. Suppliers must provide comprehensive technical and scientific documentation to support the quality attributes and performance characteristics of the endonuclease. Enzymatic activity should be demonstrated using appropriate standards or reference materials relevant to viral vector manufacturing. Overall, the endonuclease must be highly efficient, scalable, and cost-effective, and suitable for the manufacture of clinical-grade viral vectors. Appropriate analytical methods must also be available to support testing of product quality and residual endonuclease levels in drug products intended for human clinical use, in accordance with applicable national and international regulatory requirements. ### Planning Information Interested suppliers are asked to express their interest to rowena.thomas@nhsbt.nhs.uk by 5pm on Friday 31st July 2026. Suppliers expressing an interest will be invited to attend an early market engagement exercise supplier meeting during the week of August 2026 (note: date to be arranged). Prior to this session, interested suppliers will be provided with a draft specification of requirements and short questionnaire related to requirements. There is no guarantee that a formal procurement process will be launched as a result of this early market engagement exercise, nor that any contract(s) will be placed. No remuneration or compensation etc will be paid to organisations who take part in this early market engagement exercise. Suppliers should take part in this process only on the basis that they fully understand and accept this position. ## Key Details | Field | Value | | --- | --- | | Publication source | Find A Tender Service | | Latest notice | https://www.find-tender.service.gov.uk/Notice/052527-2026 | | Notice type | UK2 - Preliminary Market Engagement Notice | | Procurement type | Standard | | Procurement category | Goods | | Procurement method | Not Specified | | Procurement method details | Not specified | | Tender suitability | SME | | Awardee scale | Not specified | | All stages | Planning | ## Dates | Field | Value | | --- | --- | | Publication date | 3 Jun 2026 | | Submission deadline | Not specified | | Future notice date | 1 Oct 2026 | | Award date | Not specified | | Contract period | 1 Jan 2027 - 31 Dec 2030 | | Recurrence | Not specified | ## Values | Field | Value | | --- | --- | | Tender value | £87,500 | | Lots value | Not specified | | Awards value | Not specified | | Contracts value | Not specified | ## Status | Field | Value | | --- | --- | | Tender status | Planning | | Lots status | Planning | | Awards status | Not specified | | Contracts status | Not specified | ## Buyer | Field | Value | | --- | --- | | Main buyer | NHS BLOOD AND TRANSPLANT | | Locality | BRISTOL | | Post town | Bristol | | Postcode | BS34 7QH | | Country | England | | ITL 1 | TLK South West (England) | | ITL 2 | TLK5 West of England | | ITL 3 | TLK52 Bath & North East Somerset and South Gloucestershire | | Local authority | South Gloucestershire | | Electoral ward | Filton | | Westminster constituency | Filton and Bradley Stoke | | Delivery location | Not specified | ## CPV Codes ### Divisions - 33 - Medical equipments, pharmaceuticals and personal care products ### Codes - 33696000 - Reagents and contrast media - 33696300 - Chemical reagents ## Release History - 3 Jun 2026 at 16:30 - Planning - UK2 - Preliminary Market Engagement Notice - https://www.find-tender.service.gov.uk/Notice/052527-2026 ## Documents - https://www.find-tender.service.gov.uk/Notice/052527-2026 3rd June 2026 - Preliminary market engagement notice on Find a Tender ## Notice URLs - https://www.legislation.gov.uk/ukpga/2023/54/contents - https://www.nhsbt.nhs.uk/ ## Provenance This Markdown file is an alternate public rendering of the D3 Tenders contract record. The canonical page is https://d3tenders.com/contract/?ocid=ocds-h6vhtk-06ace0. The underlying structured data is available as OCDS JSON at https://d3tenders.com/contract/ocds-h6vhtk-06ace0.json.